Dilation of fusion pores by crowding of SNARE proteins

  1. Zhenyong Wu
  2. Oscar D Bello
  3. Sathish Thiyagarajan
  4. Sarah Marie Auclair
  5. Wensi Vennekate
  6. Shyam S Krishnakumar
  7. Ben O'Shaughnessy
  8. Erdem Karatekin  Is a corresponding author
  1. School of Medicine, Yale University, United States
  2. Yale University, United States
  3. Columbia University, United States

Abstract

Hormones and neurotransmitters are released through fluctuating exocytotic fusion pores that can flicker open and shut multiple times. Cargo release and vesicle recycling depend on the fate of the pore, which may reseal or dilate irreversibly. Pore nucleation requires zippering between vesicle-associated v- and target membrane t-SNAREs, but the mechanisms governing the subsequent pore dilation are not understood. Here, we probed dilation of single fusion pores using v-SNARE-reconstituted ~23 nm diameter discoidal nanolipoprotein particles (vNLPs) as fusion partners with cells ectopically expressing cognate, 'flipped' t-SNAREs. Pore nucleation required a minimum of 2, and reached a maximum above ~4 copies per face, but the probability of pore dilation was far from saturating at 15 copies, the NLP capacity. Our experimental and computational results suggest SNARE availability may be pivotal in determining whether neurotransmitters or hormones are released through a transient (kiss & run) or an irreversibly dilating pore (full fusion).

Article and author information

Author details

  1. Zhenyong Wu

    Department of Cellular and Molecular Physiology, School of Medicine, Yale University, New Haven, United States
    Competing interests
    The authors declare that no competing interests exist.
  2. Oscar D Bello

    Nanobiology Institute, Yale University, West Haven, United States
    Competing interests
    The authors declare that no competing interests exist.
  3. Sathish Thiyagarajan

    Department of Physics, Columbia University, New York, United States
    Competing interests
    The authors declare that no competing interests exist.
  4. Sarah Marie Auclair

    Nanobiology Institute, Yale University, West Haven, United States
    Competing interests
    The authors declare that no competing interests exist.
  5. Wensi Vennekate

    Department of Cellular and Molecular Physiology, School of Medicine, Yale University, New Haven, United States
    Competing interests
    The authors declare that no competing interests exist.
  6. Shyam S Krishnakumar

    Nanobiology Institute, Yale University, West Haven, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-6148-3251
  7. Ben O'Shaughnessy

    Department of Chemical Engineering, Columbia University, New York, United States
    Competing interests
    The authors declare that no competing interests exist.
  8. Erdem Karatekin

    Department of Cellular and Molecular Physiology, School of Medicine, Yale University, New Haven, United States
    For correspondence
    erdem.karatekin@yale.edu
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-5934-8728

Funding

National Institute of General Medical Sciences (R01GM108954)

  • Erdem Karatekin

Kavli Foundation (Neuroscience Scholar Award)

  • Erdem Karatekin

Deutsche Forschungsgemeinschaft (VE760/1-1)

  • Wensi Vennekate

National Institute of Diabetes and Digestive and Kidney Diseases (R01DK027044)

  • Shyam S Krishnakumar

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Copyright

© 2017, Wu et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 2,124
    views
  • 554
    downloads
  • 58
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Zhenyong Wu
  2. Oscar D Bello
  3. Sathish Thiyagarajan
  4. Sarah Marie Auclair
  5. Wensi Vennekate
  6. Shyam S Krishnakumar
  7. Ben O'Shaughnessy
  8. Erdem Karatekin
(2017)
Dilation of fusion pores by crowding of SNARE proteins
eLife 6:e22964.
https://doi.org/10.7554/eLife.22964

Share this article

https://doi.org/10.7554/eLife.22964

Further reading

    1. Structural Biology and Molecular Biophysics
    Shristi Pawnikar, Brenda S Magenheimer ... Yinglong Miao
    Research Article

    Polycystin-1 (PC1) is the protein product of the PKD1 gene whose mutation causes autosomal dominant Polycystic Kidney Disease (ADPKD). PC1 is an atypical G protein-coupled receptor (GPCR) with an autocatalytic GAIN domain that cleaves PC1 into extracellular N-terminal and membrane-embedded C-terminal (CTF) fragments. Recently, activation of PC1 CTF signaling was shown to be regulated by a stalk tethered agonist (TA), resembling the mechanism observed for adhesion GPCRs. Here, synthetic peptides of the first 9- (p9), 17- (p17), and 21-residues (p21) of the PC1 stalk TA were shown to re-activate signaling by a stalkless CTF mutant in human cell culture assays. Novel Peptide Gaussian accelerated molecular dynamics (Pep-GaMD) simulations elucidated binding conformations of p9, p17, and p21 and revealed multiple specific binding regions to the stalkless CTF. Peptide agonists binding to the TOP domain of PC1 induced close TOP-putative pore loop interactions, a characteristic feature of stalk TA-mediated PC1 CTF activation. Additional sequence coevolution analyses showed the peptide binding regions were consistent with covarying residue pairs identified between the TOP domain and the stalk TA. These insights into the structural dynamic mechanism of PC1 activation by TA peptide agonists provide an in-depth understanding that will facilitate the development of therapeutics targeting PC1 for ADPKD treatment.

    1. Structural Biology and Molecular Biophysics
    Artem N Bonchuk, Konstantin I Balagurov ... Pavel G Georgiev
    Research Article Updated

    BTB (bric-a-brack, Tramtrack, and broad complex) is a diverse group of protein-protein interaction domains found within metazoan proteins. Transcription factors contain a dimerizing BTB subtype with a characteristic N-terminal extension. The Tramtrack group (TTK) is a distinct type of BTB domain, which can multimerize. Single-particle cryo-EM microscopy revealed that the TTK-type BTB domains assemble into a hexameric structure consisting of three canonical BTB dimers connected through a previously uncharacterized interface. We demonstrated that the TTK-type BTB domains are found only in Arthropods and have undergone lineage-specific expansion in modern insects. The Drosophila genome encodes 24 transcription factors with TTK-type BTB domains, whereas only four have non-TTK-type BTB domains. Yeast two-hybrid analysis revealed that the TTK-type BTB domains have an unusually broad potential for heteromeric associations presumably through a dimer-dimer interaction interface. Thus, the TTK-type BTB domains are a structurally and functionally distinct group of protein domains specific to Arthropodan transcription factors.